Halozyme wins court order to block Merck's injected Keytruda in select European marketsReuters • 10/07/26
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European MarketsPRNewsWire • 10/07/26
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® TechnologyPRNewsWire • 10/06/26
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?Zacks Investment Research • 09/23/26
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033PRNewsWire • 09/18/26
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033PRNewsWire • 09/16/26
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeeking Alpha • 09/16/26
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/09/26
AI Exhaustion? 3 Healthcare Stocks With 38% EPS Growth That Could Be The CureSeeking Alpha • 09/01/26
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"Zacks Investment Research • 08/31/26
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great ChoiceZacks Investment Research • 08/28/26
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and PrecigenZacks Investment Research • 08/27/26